

South Carolina
Department of Health and Human Services
1801 Main Street
Columbia, South Carolina 29201-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
May 7, 2025
MINUTES

- I. Welcome and Call to order..... Edward Behling, MD
- Called to order at 4:09 pm.

Freedom of Information Act/Americans with Disabilities Act Compliance Pledge – This body's official minutes will indicate that this meeting is in compliance with the Freedom of Information Act's mandate that the public be notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

- II. Roll Call Kimberly Bristow, RPh
- Committee members were encouraged to attend future meetings in person.

Committee Members Present:

Edward Behling, MD	Kelly Barth, DO	Duncan Norton, MD
Heather Hembree, PharmD	Divya Ahuja, MD	Philip Mubarak, MD
Katherine Lewis, MD	Jony Bolinger, MD	Patricia Witherspoon, MD

SC DHHS Staff:

Ashley Sirianni, DNP, FNP-BC
Kevin Wessinger, MD
Kimberly Bristow, RPh
Sarah Hearn-Bailey, Esq.
Brandie Crider, BSBA, CPhT
Tawanna Zeigler, MHSA, CPhT

PRIME:

Lori Ash
Blake Cook, RPh
Lisa Correll, PharmD
Alexis Jones, MHA, MA, CPhT

- III. Approval of Minutes from February 5, 2025..... P&T Committee
- The draft minutes from the previous P&T Committee meeting February 5, 2025, were emailed to the members for review prior to the meeting.
 - Philip Mubarak, MD motioned to approve the previous P&T meeting minutes and Duncan Norton, MD seconded the motion for approval. The minutes were approved unanimously.
- IV. State Updates Dr. Kevin Wessinger and Kim Bristow, RPh
- Dr. Wessinger notified committee members that Kim Bristow is now South Carolina Department of Health and Human Services Director of Pharmacy Services. He also commented that the state will post Kim's previous position.
 - Mrs. Bristow notified committee members that LifeScan products will be removed from preferred diabetic supplies while Roche and Trividia products will continue to be preferred. This change will be effective 7/1/2025. She also informed committee members that Finacea® gel is no longer manufactured. It will be removed from the sPDL, and generic azelaic acid gel will remain as preferred.
- V. Pharma Updates..... Lisa Correll, PharmD
- Dr. Correll informed the committee that the State plans to continue utilizing the randomization process for meeting requests in 2025. There will be one 40-minute meeting per entity per year. Any questions or concerns can be directed to scpharma@primetherapeutics.com.
- VI. New Drugs to Market..... Lisa Correll, PharmD
- Alyftrek™ (vanzacaftor, tezacaftor, and deutivacaftor)
 - Tryngolza™ (olezarsen)
 - Ctexli™ (chenodiol)
 - Symbravo™ (rizatriptan benzoate/meloxicam)
 - Zunveyl™ (benzgalantamine) DR
- VII. Drug Classes for Re-Review Lisa Correll, PharmD
- Immunomodulators, Topical Atopic Dermatitis
 - Joe Cirrincione, PharmD, MBA from Incyte presented on Opzelura®. There were no questions for the speaker.
 - Adding Pimecrolimus cream (generic for Elidel®) and Tacrolimus ointment (generic for Protopic®) as preferred.
 - Duncan Norton, MD motioned for this to be approved, and Patricia Witherspoon, MD seconded the motion for approval. This change was approved unanimously.
 - Steroids, Medium Potency
 - No speaker/presenter.

- Adding fluocinolone cream, ointment, and solution (Synalar®) and fluticasone cream and ointment (Cutivate®) as preferred.
 - Duncan Norton, MD motioned for this change to be accepted and Philip Mubarak, MD seconded the motion for approval. This change was approved unanimously.
- Neuropathic Pain
 - No speaker/presenter.
 - Adding Journavx® tablet as preferred.
 - There was a robust conversation regarding the drug (Class Placement), indication, duration, etc. The final recommendation was to include as a Preferred product only if limit of 14-day supply/60 days was clearly noted on the sPDL and the therapeutic class was changed or a separate therapeutic class was created. Also, the State will monitor claims data in the interim and report information at the August P&T.
- Corticosteroids, Inhaler Devices
 - No speaker/presenter.
 - Adding Pulmicort® Flexhaler as preferred.
 - Duncan Norton, MD noted dry powder inhalers are difficult for kids.
 - Philip Mubarak, MD motioned for this change to be accepted and Katherine Lewis, MD seconded the motion for approval. This change was approved unanimously.
- Anti-Migraine CGRP Modulators
 - There were two speakers for this therapeutic class. Kirk Latibeaudiere, PharmD from Teva presented Ajovy®, and Olaide Akingbade, PharmD from AbbVie presented Qulipta®. There were no questions for the speakers.
 - Split Anti-Migraine, CGRP Modulators into Acute and Preventive treatment.
 - Preventative: Adding Ajovy® and Qulipta® tablets as preferred.
 - Dr. Akingbade clarified that Qulipta® carries the indication for preventative treatment only.
 - Acute: No changes
 - Philip Mubarak, MD motioned for these changes to be accepted and Katherine Lewis, MD and Duncan Norton, MD seconded the motion for approval. This change was approved unanimously.
- ACE Inhibitors & Combinations
 - No speaker/presenter.

- Adding Ramipril (Altace®) as preferred.
 - Duncan Norton, MD motioned for this change to be accepted and Philip Mubarak, MD seconded the motion for approval. This change was approved unanimously.
- Beta Adrenergic Devices, Short-Acting Inhalers
 - No speaker/presenter.
 - Adding Albuterol HFA inhaler (Proair® HFA) and Albuterol HFA inhaler (Ventolin® HFA) as preferred.
 - Duncan Norton, MD motioned for this change to be accepted and Philip Mubarak, MD seconded the motion for approval. This change was approved unanimously.

VIII. Brand to Generic Switch Blake Cook, RPh

- Effective 7/1/25:
 - Generic Rufinamide suspension (Banzel®) will move to preferred with brand moving to nonpreferred (*clinical criteria will remain in effect*)
 - Olmesartan/HCTZ (Benicar HCT®) will move to preferred with brand moving to nonpreferred.
 - Esomeprazole (Nexium®) packets for suspension will move to preferred with brand moving to nonpreferred.
 - Sirolimus (Rapamune®) tablets will move to preferred with brand moving to nonpreferred.
 - P &T member requests to monitor and report the brand and generic utilization of these medications.
 - Vigabatrin tabs (Sabril®) will move to preferred with brand moving to nonpreferred (*clinical criteria will remain in effect*).
 - Asenapine SL (Saphris®) will move to preferred with brand moving to nonpreferred.
 - Generic Scopolamine patch will move to preferred with brand remaining as preferred (co-preferred products).

IX. Housekeeping.....Blake Cook, RPh

- Pharma mailbox: scpharma@primetherapeutics.com
- Effective 7/1/2025 Brand to generic switches and the addition of Journavx® as preferred.
- All other category changes discussed will be effective 10/1/2025.

X. Next P&T Meeting will be held on Wednesday, August 6, 2025, at 4pm.

- All P&T Committee members are encouraged to attend in person.

XI. Open Discussion

Dr. Behling mentioned a prior topic of discussion on 340B, and Mrs. Bristow confirmed the state continues to work with providers regarding those items. Dr. Ahuja mentioned challenges encountered with HCV requests and criteria. Providers are encouraged to route issues and concerns to the State for research and review.

XII. Adjournment

- Meeting adjourned at 5:37 pm.